The pandemic has accelerated progress in the field of lipid nanoparticles (LNP), and now CRISPR-based treatments are set to reap the benefits.
Continue readingLipid nanoparticles beyond Covid vaccines
Reply
Author Archives: Anna Meldolesi
BananApocalypse – How concerned should we be?
The alarm about the impending extinction of bananas has been raised over and over in the media over the past decade. How worried do we need to be? And what are plant geneticists doing to ensure long life for this fruit loved by consumers around the world and celebrated by so many artists?
Continue readingXenografts – here’s where we stand
David Bennett, the first patient transplanted with a genetically edited pig heart, died on March 8 last year, two months after the surgery, presumably from a latent pig virus (a problem that does not seem hard to solve with more stringent protocols and screening, as Linda Scobie explained to me a few months ago). Since then, experimental transplants have continued in brain-dead patients who had donated their bodies to research. After xenokidneys with a single genetic modification transplanted in late 2021, in the summer of 2022 it was the turn of ten edits xenohearts. The state of the art now is that the potential of the approach still appears high, as does the morale of specialists.
Continue readingJust ignore He Jiankui, don’t feed his ego
The Chinese scientist who edited the CRISPR babies was released from prison last spring. He tweets lightheartedly announcing that he has opened a new lab in Beijing. He claims to be dedicated to rare diseases. He is looking for funding that hopefully no one wants to give him. In the rogue experiment that made him famous, he violated so many ethical principles that the only thing one can hope for is that he changes jobs. Is it appropriate for influential newspapers and prestigious institutions to give him a limelight for this attempt to come back on the scene?
Continue readingDrought research – persist to resist
Beating the heat is one of the goals most vigorously pursued by plant geneticists. A solution is not yet in sight, but after so many years of research, it is clear that there are several avenues worth exploring. The three most important things are testing, testing, testing.
The first consideration is that plants can adopt different strategies to survive when water is scarce. You can distinguish between drought resistance and water use efficiency, or go subtle by talking about drought avoidance, drought escape, and drought tolerance.
Another basic premise is that drought can vary in intensity and duration, so that a plant capable of tolerating moderate stress may still succumb under more extreme conditions. Further complicating matters is the fact that, to be adopted by farmers, future crops will have to prove not only more resilient but also as productive as the varieties they are intended to replace. Two strategies are being pursued at the University of Milan with the help of CRISPR.
A decade of CRISPR is only the beginning
CRISPR past, present, and future according to the review by Jennifer Doudna and Joy Y. Wang just published in Science. This is the original caption: “The past decade of CRISPR technology has focused on building the platforms for generating gene knockouts, creating knockout mice and other animal models, genetic screening, and multiplexed editing. CRISPR’s applications in medicine and agriculture are already beginning and will serve as the focus for the next decade as society’s demands drive further innovation in CRISPR technology.”
Continue readingCRISPR aims straight for the heart
The latest challenge is protecting damaged tissue immediately after a heart attack with the help of base editing (see the paper published in Science by Eric Olson’s group at the University of Texas Southwestern Medical Center). But there are hundreds of devastating diseases that affect the heart or other muscles and are caused by mutations that could be fixed by CRISPR-based tools (see this paper in Science Trsnslational Medicine for example). From Duchenne dystrophy to cardiomyopathies, some preliminary results are very encouraging.
Learn more reading the article on the Science paper published by El Pais and watching this video with Olson explaining his studies, especially on Duchenne muscular dystrophy.
Domesticaton in the CRISPR era
The world’s food supply depends on about 150 plant species, but this number could increase, even considerably. In fact, 250 species are considered to be fully domesticated, while 7,000 are semi-domesticated and 50,000 are edible. In the genomic era domestication may not require centuries and millennia, as was the case in the early days of agriculture. The process could happen at an accelerated pace, within a few years, taking advantage of modern knowledge about useful traits and new tecnologies such as gene editing.
Continue readingCRISPR good and bad news as 2023 starts
Nature suggests a number of science events to watch for in the new year. Among the developments set to shape biomedical research in 2023 we will hopefully welcome next-generation mRNA-based vaccines, the updated list of WHO priority pathogens and promising candidate drugs for Alzheimer’s. Gene editing is also not missing, with the the first approval of a CRISPR-based therapy a mere 10 years after the Doudna-Charpentier invention (more about exa-cel here).
Continue readingFestive feelings from CRISPeR Frenzy!
Emmanuelle Charpentier and Jennifer Doudna visiting the art work un|fold (Nobel Week Lights 2022, Stockholm). The sound and light sculpture is inspired by their research on genome editing.
CRISPeR FRENZY 